- AuthorisedPhase I and Phase II (Integrated)- First administration to humans
An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
This study is testing a new gene therapy for men aged 18 and over with X-linked Hyper IgM Syndrome Type 1 (HIGM1). It uses altered immune cells to see if it's safe and helps their immune system work better over two years, by checking for side effects and infections.
For: X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)Italy - AuthorisedTherapeutic confirmatory (Phase III)
A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. "BAZOOKA_221"
This study looks at how well people's bodies react to a rabies booster shot if they've already had rabies vaccination at least five years ago. We are checking different ways of giving the booster to see which works best to protect against rabies.
For: Rabies infection/prophylaxisBelgium